95
Participants
Start Date
September 28, 2017
Primary Completion Date
October 1, 2025
Study Completion Date
May 31, 2026
Cyclophosphamide
Chemotherapy
Bortezomib
Chemotherapy
Lenalidomide
Chemotherapy
Daratumumab
Chemotherapy
Dexamethasone
Chemotherapy
Melphalan
Chemotherapy
Filgrastim
Haematopoietic agent for the stem cell harvest
Queen Elizabeth Hospital, Birmingham
Birmingham Heartlands Hospital, Birmingham
Blackpool Victoria Hospital, Blackpool
Royal Bournemouth Hospital, Bournemouth
Bristol Haematology & Oncology Centre, Bristol
Beatson Oncology Centre, Glasgow
Kings College Hosptial, London
Manchester Royal Infirmary, Manchester
The Christie Hospital, Manchester
Norfolk and Norwich University Hospital, Norwich
Nottingham University Hosptial, Nottingham
Churchill Hospital, Oxford
Derriford Hospital, Plymouth
Royal Stoke Hospital, Stoke-on-Trent
Royal Hampshire County Hospital, Bournemouth
Ninewells Hospital, Dundee
Kettering General Hosptial, Kettering
Leicester Royal Infirmary, Leicester
Southampton General Hospital, Southampton
Royal Marsden Hospital, Sutton
Worcester Royal Hospital, Worcester
Collaborators (1)
Myeloma UK
OTHER
Celgene
INDUSTRY
Janssen, LP
INDUSTRY
University of Leeds
OTHER